Citations

Showing 10 of 108119 citations.

SERUM PARATHYROID HORMONE LEVELS IN ACQUIRED VITAMIN D DEFICIENCY OF INFANCY
Arnaud, Claude D., Glorieux, Francis H. , Scriver, Charles R.

Mayo Clinic

Pediatrics | December 8, 2021 | Volume: 49 | Issue: 6 | Pages: 837-840

10.1542/peds.49.6.837 Get It

The later stages of the vitamin D deficiency syndrome during infancy are associated with impaired renal tubular reabsorption of amino acids, phosphate, and other metabolites. Secondary hyperparathyroidism has been implicated as the cause of the renal abnormality. Serum immunoreactive parathyroid hormone levels are elevated in infants with vitamin D deficiency (60 to 238 µl Eq/ml; normal < 40 µl q/ml). The highest levels were found in the more advanced stages of vitamin D deficiency.
THE PEDIATRICIAN AND ATHEROSCLEROSIS
Mitchell, Shiela C., Blount, S.Gilbert, Blumenthal, Sidney, Jesse, Mary Jane, Weidman, William H.

Mayo Clinic

Pediatrics | December 8, 2021 | Volume: 49 | Issue: 2 | Pages: 165-168

10.1542/peds.49.2.165 Get It

The incidence of premature disability and death from complications of atherosclerosis in the adult American is so high that pediatricians must accept the responsibility of finding the threatened child and, insofar as possible, reducing the future risk. The Council of Rheumatic Fever and Congenital Heart Diseases of the American Heart Association formed a Committee which, during the past 2½ years, has met with a number of different experts in the field. These presentations have been supplemented by a selected review of the literature, and a workshop made up of experts in several related fields selected from the United States and a number of foreign countries to complement the above presentations.
Influence of medical trainee sleep pattern (chronotype) on burn-out and satisfaction with work schedules: a multicentre observational study
Gohar, Ashraf, Kalot, Mohamad A. , Khan, Akram , Sider, Darby, Javed, Muhammad Ali , Wooldridge, David , Eck, Leigh M , Buckhold, Fred R. , Colaco, Brendon, Bhat, Abid, Castillo, Dubier Matos, Newman, Ross, Khan, Akram , Mustafa, Reem A , Kalot, Mohamad A , Knauert, Melissa P.

Mayo Clinic

Postgraduate Medical Journal | December 8, 2021 | Volume: 98 | Issue: 1166 | Pages: 936-941

10.1136/postgradmedj-2021-140975 | PMID 37062998 Get It

AbstractBackgroundMedical trainees’ work schedule is designed to cover duties without consideration of differences in circadian rhythms during a 24-hour period (chronotype).ObjectiveTo explore chronotype variation among medical trainees and understand its association with burn-out and schedule satisfaction.MethodsIn a multicentre observational study, we conducted two surveys between 1 October 2018 and 1 April 2019. Trainees from nine centres across the USA participated. We measured burn-out using Maslach Burnout Inventory (MBI), and trainee chronotype using the Morningness-Eveningness Questionnaire (MEQ).Results324 (32%) out of 1012 responded to our survey. Participants were 51% female and had a mean age of 30.8 years. Most participants had an intermediate MEQ type (65%). A large proportion of participants had burn-out on at least one of three tested MBI scales (62%); 5% of participants had burn-out on all three MBI scales. More participants with evening MEQ type had burn-out (66%) compared with morning MEQ type (55%), however, the results were not statically significant (p=0.294). Overall satisfaction with work shifts was 6.5 (95% CI 6.3 to 6.7), with higher satisfaction with day shift 7.7 (95% CI 7.5 to 7.9) and lowest satisfaction with overnight 24-hour call 3.5 (95% CI 3.2 to 3.9). Satisfaction was lower in trainees with burn-out 6.0 (95% CI 5.7 to 6.4), (p<0.001). In the follow-up survey, burn-out was present in at least one scale in 64% compared with 60% of respondents in the initial survey.ConclusionBurn-out is prevalent among medical trainees. Improving alignment between trainee preferences may improve performance, reduce human errors and burn-out.
Reply: Regret after Gender-affirmation Surgery: A Systematic Review and Meta-analysis of Prevalence
Escandón, Joseph M. , Bustos, Samyd S. , Mascaró, Andrés, Corral, Gabriel Del, Ciudad, Pedro , Kim, Esther A. , Langstein, Howard N. , Manrique, Oscar J. , Bustos, S S , Escandón, Joseph M , Bustos, Valeria P.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | December 8, 2021 | Volume: 9 | Issue: 11 | Pages: e3954

10.1097/gox.0000000000003954 | PMID 35028263 Get It

Candidacy for Extracorporeal Life Support in Children After Hematopoietic Cell Transplantation: A Position Paper From the Pediatric Acute Lung Injury and Sepsis Investigators Network’s Hematopoietic Cell Transplant and Cancer Immunotherapy Subgroup
Zinter, Matt S. , McArthur, Jennifer , Duncan, Christine , Adams, Roberta H. , Kreml, Erin M., Dalton, Heidi , Abdel‐Azim, Hisham , Rowan, Courtney M. , Gertz, Shira J. , Mahadeo, Kris M. , Randolph, Adrienne G. , Rajapreyar, Prakadeshwari , Steiner, Marie E. , Lehmann, Leslie , Adams, Roberta, Randolph, Adrienne G , Gertz, Shira J

Mayo Clinic

Pediatric Critical Care Medicine | December 8, 2021 | Volume: 23 | Issue: 3 | Pages: 205-213

10.1097/pcc.0000000000002865 | PMID 34878420 Get It

OBJECTIVES: The last decade has seen improved outcomes for children requiring extracorporeal life support as well as for children undergoing hematopoietic cell transplantation. Thus, given the historically poor survival of hematopoietic cell transplantation patients using extracorporeal life support, the Pediatric Acute Lung Injury and Sepsis Investigators’ hematopoietic cell transplantation and cancer immunotherapy subgroup aimed to characterize the utility of extracorporeal life support in facilitating recovery from critical cardiorespiratory illnesses in pediatric hematopoietic cell transplantation patients. DATA SOURCES: All available published data were identified using a set of PubMed search terms for pediatric extracorporeal life support and hematopoietic cell transplantation. STUDY SELECTION: All articles that provided original reports of pediatric hematopoietic cell transplantation patients who underwent extracorporeal life support were included. Sixty-four manuscripts met search criteria. Twenty-four were included as primary reports of pediatric hematopoietic cell transplantation patients who underwent extracorporeal life support (11 were single case reports, four single institution case series, two multi-institution case series, and seven registry reports from Extracorporeal Life Support Organization, Pediatric Heath Information System, and Virtual Pediatric Systems). DATA EXTRACTION: All 24 articles were reviewed by first and last authors and a spread sheet was constructed including sample size, potential biases, and conclusions. DATA SYNTHESIS: Discussions regarding incorporation of available evidence into our clinical practice were held at biannual meetings, as well as through email and virtual meetings. An expert consensus was determined through these discussions and confirmed through a modified Delphi process. CONCLUSIONS: Extracorporeal life support in hematopoietic cell transplantation patients is being used with increasing frequency and potentially improving survival. The Pediatric Acute Lung Injury and Sepsis Investigators hematopoietic cell transplantation-cancer immunotherapy subgroup has developed a framework to guide physicians in decision-making surrounding extracorporeal life support candidacy in pediatric hematopoietic cell transplantation patients. In addition to standard extracorporeal life support considerations, candidacy in the hematopoietic cell transplantation population should consider the following six factors in order of consensus agreement: 1) patient comorbidities; 2) underlying disease necessitating hematopoietic cell transplantation; 3) hematopoietic cell transplantation toxicities, 4) family and patient desires for goals of care; 5) hematopoietic cell transplantation preparatory regimen; and 6) graft characteristics. Although risk assessment may be individualized, data are currently insufficient to clearly delineate ideal candidacy. Therefore, we urge the onco-critical care community to collaborate and capture data to provide better evidence to guide physicians’ decision-making in the future.
459 Evaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither
Wright, R. Scott , Kallend, David , Ray, Kausik K. , Wijngaard, Peter, Kastelein, John J.P. , Ray, Kausik K , Leiter, Lawrence A. , Köenig, Wolfgang , Raal, Frederick J.

Mayo Clinic

European Heart Journal Supplements | December 8, 2021 | Volume: 23 | Issue: Supplement_G | Pages: No page available

10.1093/eurheartj/suab136.001 Get It

Abstract Aims Patients with diabetes (DM) and metabolic syndrome (MS) have elevated risks for atherosclerotic cardiovascular disease (ASCVD). Aggressive LDL-C lowering reduces risks. Inclisiran, a new siRNA, lowers LDL-C and was evaluated in patients with Type 2 diabetes (DM), metabolic syndrome (MS) without DM or neither (N) in the ORION-10 trial. Methods ORION-10 was a double-blind, randomized, placebo controlled trial evaluating inclisiran in 1561 patients with ASCVD on maximally tolerated therapy for lowering LDL-C. 781 inclisiran (INC) participants and 780 placebo (P) patients received 1.5 mL SQ tx at Days 1, 90, then every 6 months until Day 540. We evaluated the time adjusted change in LDL-C from baseline after Days 90–540 in DM (n = 702), MS (n = 455) and N participants (n = 404). Results There were no differences in baseline demographics and background therapies between INC and P. Statins were utilized in 89.8% INC and 88.7% of P. High intensity statins were utilized in 67.2% of INC and 68.8% of P; ezetimibe in 10.2% of NC and 9.5% of P participants. INC reduced LDL-C by − 54.4% (−58.3, −50.6 95% CI) in DM, (P < 0.001), −58.6% (−62.3, −54.8), P < 0.001 in-MS and −56.0% (−60.2, −51.7), in N subjects P < 0.001 (see Figure). Conclusions Inclisiran potently and durably reduces LDL-C across patients with DM, MS and those with neither, demonstrating potent efficacy and durability across glycaemic categories. Inclisiran may also represent a potent LDL-C lowering treatment for those with DM and MS.
Gene-mapping study of extremes of cerebral small vessel disease reveals TRIM47 as a strong candidate
Mishra, Aniket , Duplàa, Cécile , Suzuki, Hideaki , Li, Shuo , Bartz, Traci M. , Jian, Xueqiu , Zhao, Wei , Hofer, Edith , Wittfeld, Katharina , Bis, Joshua C, Adams, Hieab H.H. , Satizábal, Claudia L. , Gottesman, Rebecca F., Gampawar, Piyush , Weiß, Stefan , Yu, Miao , Lopez, Oscar L., Vernooij, Meike W. , Soumaré, Aïcha , Smith, Jennifer A. , Zhu, Yi‐Cheng , Rotter, Jerome I. , Dufouil, Carole , Maniega, Susana Muñoz , Lathrop, Mark, Boerwinkle, Erik, Schmidt, Reinhold, Ihara, Masafumi , Joutel, Anne , Tournier‐Lasserve, Elisabeth , Mosley, Thomas H. , DeCarli, Charles , Tzourio, Christophe , Kardia, Sharon L. R., Teumer, Alexander , Schmidt, Helena , Wardlaw, Joanna M. , Fornage, Myriam , Guðnason, Vilmundur , Longstreth, W.T. , Couffinhal, Thierry , Debette, Stéphanie , Zhao, Wei , Sargurupremraj, Muralidharan , DeCarli, Charles , Suzuki, Hideaki , Sargurupremraj, Muralidharan , Bülow, Robin , Weiss, Stefan , Völker, Uwe , Smith, Jennifer A , Yang, Qiong , Amouyel, Philippe , Tzourio, Christophe , Teumer, Alexander , van Duijn, Cornelia M , Matthews, Paul M , Debette, Stephanie , Wardlaw, Joanna Marguerite , Adams, Hieab H H , Satizabal, Claudia L , Rotter, Jerome I , Vojinović, Dina , Zilhäo, Nuno R. , Harris, Sarah , Auwera, Sandra Van der , Luciano, Michelle , Bis, Joshua C, Bastin, Mark E. , Beiser, Alexa , Völker, Uwe , Kacprowski, Tim , Knopman, David S. , Morris, Zoë , Hernández, Maria del Carmen Valdés , Mazoyer, Bernard , Launer, Lenore J. , Deary, Ian J. , Amouyel, Philippe , Psaty, Bruce M. , Grabe, Hans Jörgen , Duijn, Cornelia M. van , Ikram, M. Arfan , Seshadri, Sudha , Matthews, Paul M.

Mayo Clinic

Brain | December 8, 2021 | Volume: 145 | Issue: 6 | Pages: 1992-2007

10.1093/brain/awab432 | PMID 35511193 Get It

Abstract Cerebral small vessel disease is a leading cause of stroke and a major contributor to cognitive decline and dementia, but our understanding of specific genes underlying the cause of sporadic cerebral small vessel disease is limited. We report a genome-wide association study and a whole-exome association study on a composite extreme phenotype of cerebral small vessel disease derived from its most common MRI features: white matter hyperintensities and lacunes. Seventeen population-based cohorts of older persons with MRI measurements and genome-wide genotyping (n = 41 326), whole-exome sequencing (n = 15 965), or exome chip (n = 5249) data contributed 13 776 and 7079 extreme small vessel disease samples for the genome-wide association study and whole-exome association study, respectively. The genome-wide association study identified significant association of common variants in 11 loci with extreme small vessel disease, of which the chr12q24.11 locus was not previously reported to be associated with any MRI marker of cerebral small vessel disease. The whole-exome association study identified significant associations of extreme small vessel disease with common variants in the 5′ UTR region of EFEMP1 (chr2p16.1) and one probably damaging common missense variant in TRIM47 (chr17q25.1). Mendelian randomization supports the causal association of extensive small vessel disease severity with increased risk of stroke and Alzheimer’s disease. Combined evidence from summary-based Mendelian randomization studies and profiling of human loss-of-function allele carriers showed an inverse relation between TRIM47 expression in the brain and blood vessels and extensive small vessel disease severity. We observed significant enrichment of Trim47 in isolated brain vessel preparations compared to total brain fraction in mice, in line with the literature showing Trim47 enrichment in brain endothelial cells at single cell level. Functional evaluation of TRIM47 by small interfering RNAs-mediated knockdown in human brain endothelial cells showed increased endothelial permeability, an important hallmark of cerebral small vessel disease pathology. Overall, our comprehensive gene-mapping study and preliminary functional evaluation suggests a putative role of TRIM47 in the pathophysiology of cerebral small vessel disease, making it an important candidate for extensive in vivo explorations and future translational work.
Right Heart Dysfunction in Adults With Coarctation of Aorta: Prevalence and Prognostic Implications
Egbe, Alexander C. , Miranda, William R. , Jain, C. Charles , Connolly, Heidi M.

Mayo Clinic

Circulation: Cardiovascular Imaging | December 8, 2021 | Volume: 14 | Issue: 12 | Pages: 1100-1108

10.1161/circimaging.121.013075 | PMID 34875855 Get It

Background: Chronic elevation of left heart filling pressure causes pulmonary vascular remodeling, pulmonary hypertension, and right heart dysfunction. Although diastolic dysfunction is relatively common in patients with coarctation of aorta, there are limited data about the prevalence and prognostic implications of pulmonary hypertension and right heart dysfunction in this population. The purpose of the study was to assess right heart function and hemodynamics in patients with coarctation of aorta and to determine the relationship between right heart indices and cardiovascular events defined as heart failure hospitalization, heart transplant, or cardiovascular death. Methods: Right heart structure, function, and hemodynamics were assessed with these indices: right atrial volume, right atrial pressure, right atrial reservoir strain, right ventricular global longitudinal strain, right ventricular end-diastolic area, right ventricular systolic pressure, and tricuspid regurgitation severity. Right heart hemodynamic score, range 0 to 5, was generated based on the correlation between the right heart indices and cardiovascular events, using half of the cohort (derivation cohort, n=411), and then tested on the validation cohort (n=410). The goodness of fit and discrimination power was compared using C statistics and risk score. Results: The median follow-up in the derivation cohort was 8.2 (4.0–11.1) years, and 59 (14%) patients had cardiovascular events during this period. Right heart hemodynamic score was independently associated with cardiovascular events (hazard ratio, 1.64 [95% CI, 1.38–2.17]) for every unit increase in right heart hemodynamic score after adjustment for clinical and echocardiographic indices (C statistic, 0.718 [95% CI, 0.682–0.746]). The right heart hemodynamic score was also independently associated with cardiovascular events in the validation cohort (C statistic, 0.711 [95% CI, 0.679–0.741]). The C statistic difference (0.007 [95% CI, 0.014–0.022]) and risk score (0.86 [95% CI, 0.54–1.17]) suggest a good model fit. Conclusions: The current study underscores the prognostic importance of right heart dysfunction in patients with coarctation of aorta and suggests that right heart indices should be used for risks stratification in this population.